Antipodes Partners’s Boston Scientific BSX Stock Holding History

Antipodes Partners’s Portfolio BSX Stock Details BSX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,128	Closed	-$70.8K	–	133
2026 Q1	$70.8K	Buy	+1,128	New	+$90.2K	﹤0.01%	101

Other funds holding BSX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Antipodes Partners's BSX Position: Q2 2026 in Review

Antipodes Partners sold out of Boston Scientific (BSX) in Q2 2026, closing a stake of 1,128 shares — an estimated $70.8K sold.

Antipodes Partners first reported a position in BSX in Q1 2026 and held it in 1 quarter. The position peaked at $70.8K in Q1 2026. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.

Antipodes Partners reported no remaining Boston Scientific position as of Q2 2026 after selling out during the quarter.
Antipodes Partners sold 1,128 Boston Scientific shares in Q2 2026, an estimated $70.8K.
Antipodes Partners first reported a position in Boston Scientific in Q1 2026 and held it in 1 quarter.
Antipodes Partners's Boston Scientific position peaked at $70.8K in Q1 2026.
1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.

Based on Antipodes Partners's 13F filing for Q2 2026, filed 6 Aug 2026.